A phase I, randomized, ascending‐dose study to assess safety, pharmacokinetics, and activity of GDC‐8264, a RIP1 inhibitor, in healthy volunteers

• Main Authors: Nicholas S. Jones (Author), Smita Kshirsagar (Author), Vishnu Mohanan (Author), Vidya Ramakrishnan (Author), Flavia Di Nucci (Author), Ling Ma (Author), Jialin Mao (Author), Hao Ding (Author), Sha Klabunde (Author), Domagoj Vucic (Author), Lin Pan (Author), Annemarie N. Lekkerkerker (Author), Yuan Chen (Author), Michael E. Rothenberg (Author)
• Format: Book
• Published: Wiley, 2023-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Receptor‐interacting protein 1 (RIP1) is a key regulator of multiple signaling pathways that mediate inflammatory responses and cell death. RIP1 kinase activity mediates apoptosis and necroptosis induced by tumor necrosis factor (TNF)‐α, Toll‐like receptors, and ischemic tissue damage. RIP1...